PD-1 inhibitor with hyaluronidase enzyme

This page covers all PD-1 inhibitor with hyaluronidase enzyme drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PD-1; hyaluronic acid (via hyaluronidase).

Targets

PD-1; hyaluronic acid (via hyaluronidase)

Phase 3 pipeline (2)

• Nivolumab and rHuPH20 · Bristol-Myers Squibb · Oncology
  Nivolumab blocks PD-1 on immune cells to restore anti-tumor immunity, while rHuPH20 (recombinant human hyaluronidase) enhances drug penetration into tumors by degrading the hyaluronic acid-rich extracellular matrix.
• Nivolumab and Recombinant Human Hyaluronidase · SWOG Cancer Research Network · Oncology
  Nivolumab blocks PD-1 to enhance anti-tumor immunity, while recombinant human hyaluronidase improves drug penetration into tumors by degrading hyaluronic acid in the extracellular matrix.